RxDoctor Payments Data

Asra Siddiqui, MD

Internal Medicine · Newbury Park, CANPI 1649275397

Payments from drug & device makers

What this record shows

This record is dominated by education: $305 of the $452 with a category attached, or 67.5%. Medical Device Business Services, Inc. accounts for 67.5% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2022 at $348 and has fallen 92.1% since, to $28 in 2024.

$452in general payments, 2019–2025

Across 9 payments — averaging $50.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medical Device Business Services, Inc.$305
  • Abbott$95
  • Biosense Webster, Inc.$18
  • Lilly USA, LLC$15
  • Merck$12
  • Endogastric Solutions, Inc$8

What the payments were for

  • Food & beverage$14733%
  • Education$30567%

General payments by program year

19
20
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$452 in reported general payments places this provider in the 65th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California →

Medicare billing

Part B allowed, 2024
$125,815
Medicare patients
158
Services billed
1,823

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban19$31,544
ProliaDenosumab17$29,153
JanumetSitagliptin Phos/Metformin Hcl12$11,250
MyrbetriqMirabegron16$10,697
JardianceEmpagliflozin11$7,157
SynthroidLevothyroxine Sodium40$3,200
Levothyroxine Sodium156$1,892
Atorvastatin Calcium124$1,492
Estradiol22$865
LantusInsulin Glargine,hum.Rec.Anlog12$860
Gabapentin34$854
Losartan Potassium53$850
Bupropion XlBupropion Hcl32$710
Amlodipine Besylate58$578
ValacyclovirValacyclovir Hcl16$573

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanumet$12$11,25012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Newbury Park

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →